ReviewImmunology2026
Thymus and Leishmania at the Crossroads: Autoimmunity and Cancer.
Review in Immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leishmania infections profoundly reshape host immunity, yet their impact on central T-cell development remains underappreciated. The thymus, a key site for establishing a functional and self-tolerant T-cell repertoire, is highly sensitive to systemic inflammatory cues. Growing evidence indicates that parasitic diseases, including leishmaniasis, can perturb thymic structure and function through direct parasite presence or sustained inflammatory stress. Such disturbances may alter thymocyte maturation, leading to reduced T-cell output and the release of cells with aberrant specificity. Beyond compromising protective immunity, these changes may create conditions favourable to immune dysregulation, including the emergence of autoimmune manifestations and a microenvironment permissive to malignant transformation. This narrative review synthesises current findings on how Leishmania interacts with immunological tissues and highlights the thymus as a potential and overlooked target whose dysfunction may bridge infection, autoimmunity and cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.